 |
November 2024
Registration Statement No. 333-265158
Pricing Supplement dated November
21, 2024
Filed pursuant to Rule 424(b)(2) |
STRUCTURED INVESTMENTS
Opportunities in U.S. Equities
Trigger Jump Securities
Based on the Performance of the Common Stock of Repligen Corporation due May 27, 2026
Principal at Risk Securities
Unlike conventional debt securities, the securities will pay no interest
and do not guarantee any return of principal at maturity. Instead, if the final underlier value is greater than or equal to the initial
underlier value, at maturity investors will receive the stated principal amount plus a positive return equal to the fixed percentage of
43.20%. If the final underlier value is less than the initial underlier value but greater than or equal to the trigger value, which is
equal to 90% of the initial underlier value, at maturity investors will receive the stated principal amount. However, if the final underlier
value is less than the trigger value, at maturity investors will lose 1% of the stated principal amount for every 1% that the final underlier
value is less than the initial underlier value. Under these circumstances, the amount investors receive will be less than 90% of the stated
principal amount and could be zero. The securities are for investors who are willing and able to risk their principal and forgo current
income in exchange for the opportunity to receive a return equal to the fixed percentage if the final underlier value is greater than
or equal to the initial underlier value and the limited protection against loss, which applies only if the final underlier value is greater
than or equal to the trigger value. Investors may lose their entire initial investment in the
securities. Any positive return on the securities will be limited to the fixed percentage and you will not participate in any appreciation
in the value of the underlier above the fixed percentage, which may be significant. The securities are unsecured and unsubordinated debt
obligations of Barclays Bank PLC. Any payment on the securities, including any repayment of principal, is subject to the creditworthiness
of Barclays Bank PLC and is not guaranteed by any third party. If Barclays Bank PLC were to default on its payment obligations or become
subject to the exercise of any U.K. Bail-in Power (as described on page 5 of this
document) by the relevant U.K. resolution authority, you might not receive any amounts owed to you under the securities. See “Risk
Factors” and “Consent to U.K. Bail-in Power” in this document and “Risk Factors” in the accompanying prospectus
supplement.
| FINAL TERMS |
|
| Issuer: |
Barclays Bank PLC |
| Reference asset*: |
Repligen Corporation common stock (Bloomberg ticker symbol “RGEN UW<Equity>”) (the “underlier”) |
| Aggregate principal amount: |
$10,000,000 |
| Stated principal amount: |
$1,000 per security |
| Pricing date†: |
November 21, 2024 |
| Original issue date†: |
November 26, 2024 |
| Valuation date†: |
May 21, 2026 |
| Maturity date*†: |
May 27, 2026 |
| Interest: |
None |
| Payment at maturity: |
You will receive on the maturity date a cash payment per security determined
as follows:
·
If the final underlier value is greater than or equal to the initial underlier value:
$1,000 + ($1,000 × fixed percentage)
·
If the final underlier value is less than the initial underlier value but greater than or equal to the trigger value:
$1,000
·
If the final underlier value is less than the trigger value:
$1,000 × underlier performance factor
Under these circumstances, the payment at maturity
will be less than the stated principal amount of $1,000 and will represent a loss of more than 10%, and possibly all, of an investor’s
initial investment. Investors may lose their entire initial investment in the securities. Any payment on the securities, including
any repayment of principal, is not guaranteed by any third party and is subject to (a) the creditworthiness of Barclays Bank PLC and (b)
the risk of exercise of any U.K. Bail-in Power by the relevant U.K. resolution authority.
|
| U.K. Bail-in Power acknowledgment: |
Notwithstanding and to the exclusion of any other term of the securities or any other agreements, arrangements or understandings between Barclays Bank PLC and any holder or beneficial owner of the securities (or the trustee on behalf of the holders of the securities), by acquiring the securities, each holder and beneficial owner of the securities acknowledges, accepts, agrees to be bound by and consents to the exercise of, any U.K. Bail-in Power by the relevant U.K. resolution authority. See “Consent to U.K. Bail-in Power” on page 5 of this document. |
| Fixed percentage: |
43.20% |
| Trigger value*: |
$127.58, which is 90% of the initial underlier value (rounded to two decimal places) |
| Underlier performance factor: |
final underlier value / initial underlier value |
| Initial underlier value*: |
$141.76, which is the closing price of the underlier on the pricing date |
| Final underlier value*: |
The closing price of the underlier on the valuation date |
| |
(terms continued on the next page) |
| Commissions and initial issue price: |
Initial issue price(1) |
Price to public(1) |
Agent’s commissions |
Proceeds to issuer |
| Per security |
$1,000 |
$1,000 |
$20.00(2)
$5.00(3) |
$975.00 |
| Total |
$10,000,000 |
$10,000,000 |
$250,000 |
$9,750,000 |
| |
|
|
|
|
|
| (1) | Our estimated value of the securities on the pricing date, based on our internal pricing models, is $954.50 per security. The estimated
value is less than the initial issue price of the securities. See “Additional Information Regarding Our Estimated Value of the Securities”
on page 4 of this document. |
| (2) | Morgan Stanley Wealth Management and its financial advisors will collectively receive from the agent, Barclays Capital Inc., a
fixed sales commission of $20.00 for each security they sell. See “Supplemental Plan of Distribution” in this document. |
| (3) | Reflects a structuring fee payable to Morgan Stanley Wealth Management by the agent or its affiliates of $5.00 for each security. |
One or more of our affiliates may purchase
up to 15% of the aggregate principal amount of the securities and hold such securities for investment for a period of at least 30 days.
Accordingly, the total principal amount of the securities may include a portion that was not purchased by investors on the original issue
date. Any unsold portion held by our affiliate(s) may affect the supply of securities available for secondary trading and, therefore,
could adversely affect the price of the securities in the secondary market. Circumstances may occur in which our interests or those of
our affiliates could be in conflict with your interests.
Investing in the securities involves risks not associated
with an investment in conventional debt securities. See “Risk Factors” beginning on page 11 of this document and beginning
on page S-9 of the prospectus supplement. You should read this document together with the related prospectus and prospectus supplement,
each of which can be accessed via the hyperlinks below, before you make an investment decision.
The securities will not be listed on any U.S. securities exchange
or quotation system. Neither the U.S. Securities and Exchange Commission (the “SEC”) nor any state securities commission has
approved or disapproved of the securities or determined that this document is truthful or complete. Any representation to the contrary
is a criminal offense.
We may use this document in the initial sale of the securities. In
addition, Barclays Capital Inc. or another of our affiliates may use this document in market resale transactions in any of the securities
after their initial sale. Unless we or our agent informs you otherwise in the confirmation of sale, this document is being used in a market
resale transaction.
The securities constitute our unsecured and unsubordinated obligations.
The securities are not deposit liabilities of Barclays Bank PLC and are not covered by the U.K. Financial Services Compensation Scheme
or insured by the U.S. Federal Deposit Insurance Corporation or any other governmental agency or deposit insurance agency of the United
States, the United Kingdom or any other jurisdiction.
Trigger Jump Securities Based on the Performance of the Common Stock of Repligen Corporation due May 27, 2026
Principal at Risk Securities
| Terms continued from previous page: |
| Closing price*: |
Closing price has the meaning set forth under “Reference Assets—Equity Securities—Special Calculation Provisions” in the prospectus supplement. |
| Additional terms: |
Terms used in this document, but not defined herein, will have the meanings ascribed to them in the prospectus supplement. |
| CUSIP / ISIN: |
06745YPB2 / US06745YPB29 |
| Listing: |
The securities will not be listed on any securities exchange. |
| Selected dealer: |
Morgan Stanley Wealth Management (“MSWM”) |
| * |
In the case of certain corporate events related to the underlier, the calculation agent may adjust any variable, including but not limited to, the underlier, initial underlier value, final underlier value, trigger value and closing price of the underlier if the calculation agent determines that the event has a diluting or concentrative effect on the theoretical value of the shares of the underlier. The calculation agent may accelerate the maturity date upon the occurrence of certain reorganization events and additional adjustment events. For more information, see “Reference Assets—Equity Securities—Share Adjustments Relating to Securities with an Equity Security as a Reference Asset” in the accompanying prospectus supplement. |
| † |
The valuation date may be postponed if the valuation date is not a scheduled trading day or if a market disruption event occurs on the valuation date as described under “Reference Assets—Equity Securities—Market Disruption Events for Securities with an Equity Security as a Reference Asset” in the accompanying prospectus supplement. In addition, the maturity date will be postponed if that day is not a business day or if the valuation date is postponed as described under “Terms of the Notes—Payment Dates” in the accompanying prospectus supplement.
|
Barclays Capital Inc.
|
Trigger Jump Securities Based on the Performance of the Common Stock of Repligen Corporation due May 27, 2026
Principal at Risk Securities
Additional Terms of the Securities
You should read this document together with the prospectus dated May
23, 2022, as supplemented by the prospectus supplement dated June 27, 2022 relating to our Global Medium-Term Notes, Series A, of which
the securities are a part. This document, together with the documents listed below, contains the terms of the securities and supersedes
all prior or contemporaneous oral statements as well as any other written materials including preliminary or indicative pricing terms,
correspondence, trade ideas, structures for implementation, sample structures, brochures or other educational materials of ours. You should
carefully consider, among other things, the matters set forth under “Risk Factors” in the prospectus supplement, as the securities
involve risks not associated with conventional debt securities. We urge you to consult your investment, legal, tax, accounting and other
advisors before you invest in the securities.
You may access these documents on the SEC website at www.sec.gov as
follows (or if such address has changed, by reviewing our filings for the relevant date on the SEC website):
Our SEC file number is 1-10257 and our Central Index Key, or CIK, on
the SEC website is 0000312070. As used in this document, “we,” “us” and “our” refer to Barclays Bank
PLC.
In connection with this offering, Morgan Stanley Wealth Management is
acting in its capacity as a selected dealer.
Trigger Jump Securities Based on the Performance of the Common Stock of Repligen Corporation due May 27, 2026
Principal at Risk Securities
Additional Information Regarding Our Estimated Value
of the Securities
Our internal pricing models take into account a number of variables
and are based on a number of subjective assumptions, which may or may not materialize, typically including volatility, interest rates
and our internal funding rates. Our internal funding rates (which are our internally published borrowing rates based on variables, such
as market benchmarks, our appetite for borrowing and our existing obligations coming to maturity) may vary from the levels at which our
benchmark debt securities trade in the secondary market. Our estimated value on the pricing date is based on our internal funding rates.
Our estimated value of the securities might be lower if such valuation were based on the levels at which our benchmark debt securities
trade in the secondary market.
Our estimated value of the securities on the pricing date is less than
the initial issue price of the securities. The difference between the initial issue price of the securities and our estimated value of
the securities results from several factors, including any sales commissions to be paid to Barclays Capital Inc. or another affiliate
of ours, any selling concessions, discounts, commissions or fees to be allowed or paid to non-affiliated intermediaries, the estimated
profit that we or any of our affiliates expect to earn in connection with structuring the securities, the estimated cost that we may incur
in hedging our obligations under the securities, and estimated development and other costs that we may incur in connection with the securities.
These other costs will include a fee paid to LFT Securities, LLC, an entity in which an affiliate of Morgan Stanley Wealth Management
has an ownership interest, for providing certain electronic platform services with respect to this offering.
Our estimated value on the pricing date is not a prediction of the price
at which the securities may trade in the secondary market, nor will it be the price at which Barclays Capital Inc. may buy or sell the
securities in the secondary market. Subject to normal market and funding conditions, Barclays Capital Inc. or another affiliate of ours
intends to offer to purchase the securities in the secondary market but it is not obligated to do so.
Assuming that all relevant factors remain constant after the pricing
date, the price at which Barclays Capital Inc. may initially buy or sell the securities in the secondary market, if any, and the value
that we may initially use for customer account statements, if we provide any customer account statements at all, may exceed our estimated
value on the pricing date for a temporary period expected to be approximately 40 days after the initial issue date of the securities because,
in our discretion, we may elect to effectively reimburse to investors a portion of the estimated cost of hedging our obligations under
the securities and other costs in connection with the securities that we will no longer expect to incur over the term of the securities.
We made such discretionary election and determined this temporary reimbursement period on the basis of a number of factors, which may
include the tenor of the securities and/or any agreement we may have with the distributors of the securities. The amount of our estimated
costs that we effectively reimburse to investors in this way may not be allocated ratably throughout the reimbursement period, and we
may discontinue such reimbursement at any time or revise the duration of the reimbursement period after the initial issue date of the
securities based on changes in market conditions and other factors that cannot be predicted.
We urge you to read “Risk Factors” beginning on page
11 of this document.
Trigger Jump Securities Based on the Performance of the Common Stock of Repligen Corporation due May 27, 2026
Principal at Risk Securities
Consent to U.K. Bail-in Power
Notwithstanding and to the
exclusion of any other term of the securities or any other agreements, arrangements or understandings between us and any holder or beneficial
owner of the securities (or the trustee on behalf of the holders of the securities), by acquiring the securities, each holder and beneficial
owner of the securities acknowledges, accepts, agrees to be bound by and consents to the exercise of, any U.K. Bail-in Power by the relevant
U.K. resolution authority.
Under the U.K. Banking Act 2009,
as amended, the relevant U.K. resolution authority may exercise a U.K. Bail-in Power in circumstances in which the relevant U.K. resolution
authority is satisfied that the resolution conditions are met. These conditions include that a U.K. bank or investment firm is failing
or is likely to fail to satisfy the Financial Services and Markets Act 2000 (the “FSMA”) threshold conditions for authorization
to carry on certain regulated activities (within the meaning of section 55B FSMA) or, in the case of a U.K. banking group company that
is a European Economic Area (“EEA”) or third country institution or investment firm, that the relevant EEA or third country
relevant authority is satisfied that the resolution conditions are met in respect of that entity.
The U.K. Bail-in Power includes
any write-down, conversion, transfer, modification and/or suspension power, which allows for (i) the reduction or cancellation of all,
or a portion, of the principal amount of, interest on, or any other amounts payable on, the securities; (ii) the conversion of all, or
a portion, of the principal amount of, interest on, or any other amounts payable on, the securities into shares or other securities or
other obligations of Barclays Bank PLC or another person (and the issue to, or conferral on, the holder or beneficial owner of the securities
such shares, securities or obligations); (iii) the cancellation of the securities and/or (iv) the amendment or alteration of the maturity
of the securities, or amendment of the amount of interest or any other amounts due on the securities, or the dates on which interest or
any other amounts become payable, including by suspending payment for a temporary period; which U.K. Bail-in Power may be exercised by
means of a variation of the terms of the securities solely to give effect to the exercise by the relevant U.K. resolution authority of
such U.K. Bail-in Power. Each holder and beneficial owner of the securities further acknowledges and agrees that the rights of the holders
or beneficial owners of the securities are subject to, and will be varied, if necessary, solely to give effect to, the exercise of any
U.K. Bail-in Power by the relevant U.K. resolution authority. For the avoidance of doubt, this consent and acknowledgment is not a waiver
of any rights holders or beneficial owners of the securities may have at law if and to the extent that any U.K. Bail-in Power is exercised
by the relevant U.K. resolution authority in breach of laws applicable in England.
For more information, please see
“Risk Factors—Risks Relating to the Issuer—You may lose some or all of your investment if any U.K. bail-in power is
exercised by the relevant U.K. resolution authority” in this document as well as “U.K. Bail-in Power,” “Risk Factors—Risks
Relating to the Securities Generally—Regulatory action in the event a bank or investment firm in the Group is failing or likely
to fail, including the exercise by the relevant U.K. resolution authority of a variety of statutory resolution powers, could materially
adversely affect the value of any securities” and “Risk Factors—Risks Relating to the Securities Generally—Under
the terms of the securities, you have agreed to be bound by the exercise of any U.K. Bail-in Power by the relevant U.K. resolution authority”
in the accompanying prospectus supplement.
Trigger Jump Securities Based on the Performance of the Common Stock of Repligen Corporation due May 27, 2026
Principal at Risk Securities
Investment Summary
Trigger Jump Securities
Principal at Risk Securities
The Trigger Jump Securities Based on the Performance of the Common Stock
of Repligen Corporation due May 27, 2026 (the “securities”) can be used:
| § | As an alternative to direct exposure to the underlier that provides for the potential of a fixed positive
return if the underlier appreciates at all (or remains flat) in lieu of full participation in any appreciation of the underlier |
| § | To enhance returns and potentially outperform the underlier in a moderately bullish scenario |
| § | To provide limited protection against a loss of principal in the event of a decline of the underlier
from the pricing date to the valuation date, but only if the final underlier value is greater than or equal to the trigger value |
Any positive return on the securities will be limited
to the fixed percentage and you will not participate in any appreciation in the value of the underlier above the fixed percentage, which
may be significant.
If the final underlier value is less than the trigger
value, the securities are exposed on a 1:1 basis to the negative performance of the underlier.
| Maturity: |
Approximately 1.5 years |
| Fixed percentage: |
43.20% |
| Trigger value: |
90% of the initial underlier value |
| Minimum payment at maturity: |
None. Investors may lose their entire initial investment in the securities. |
| Interest: |
None |
Key Investment Rationale
The securities are for investors who are willing and able to risk their
principal and forgo current income in exchange for the opportunity to receive a return equal to the fixed percentage if the final underlier
value is greater than or equal to the initial underlier value and the limited protection against loss, which applies only if the final
underlier value is greater than or equal to the trigger value. Investors may lose their entire initial investment in the securities.
The following scenarios reflect the potential payment on the securities,
if any, at maturity:
| Upside Scenario |
The final underlier value is greater than or equal to the initial underlier value. In this case, at maturity, the securities pay the stated principal amount of $1,000 plus a positive return equal to the fixed percentage of 43.20%. |
| Par Scenario |
The final underlier value is less than the initial underlier value but greater than or equal to the trigger value. In this case, at maturity, the securities pay the stated principal amount of $1,000 per security even though the value of the underlier has declined. |
| Downside Scenario |
The final underlier value is less than the trigger value. In this case, at maturity, the securities pay less than 90% of the stated principal amount and the percentage loss of the stated principal amount will be equal to the percentage decrease from the initial underlier value to the final underlier value. For example, if the final underlier value is 55% less than the initial underlier value, the securities will pay $450.00 per security, or 45% of the stated principal amount, for a loss of 55% of the stated principal amount. There is no minimum payment at maturity on the securities. Accordingly, investors could lose their entire investment in the securities. |
Trigger Jump Securities Based on the Performance of the Common Stock of Repligen Corporation due May 27, 2026
Principal at Risk Securities
Selected Purchase Considerations
The securities are not appropriate
for all investors. The securities may be an appropriate investment for you if all of the following statements are true:
| § | You do not seek an investment that produces periodic interest
or coupon payments or other sources of current income. |
| § | You anticipate that the final underlier value will be greater
than or equal to the initial underlier value, and you are willing and able to accept the risk that, if the final underlier value is less
than the trigger value, you will lose a significant portion, and possibly all, of the stated principal amount of the securities. |
| § | You understand and accept that any potential upside return
on the securities is limited to the fixed percentage, and you will not participate in any appreciation in the value of the underlier above
the fixed percentage, which may be significant. |
| § | You are willing and able to accept the risks associated with
an investment linked to the performance of the underlier, as explained in more detail in the “Risk Factors” section of this
document. |
| § | You understand and accept that you will not be entitled to
receive dividends or distributions that may be paid to holders of the underlier, nor will you have any voting rights with respect to the
issuer of the underlier. |
| § | You do not seek an investment for which there will be an
active secondary market and you are willing and able to hold the securities to maturity. |
| § | You are willing and able to assume our credit risk for all
payments on the securities. |
| § | You are willing and able to consent to the exercise of any
U.K. Bail-in Power by any relevant U.K. resolution authority. |
The securities may not
be an appropriate investment for you if any of the following statements are true:
| § | You seek an investment that produces periodic interest or
coupon payments or other sources of current income. |
| § | You seek an investment that provides for the full repayment
of principal at maturity. |
| § | You anticipate that the final underlier value will be less
than the initial underlier value, or you are unwilling or unable to accept the risk that, if the final underlier value is less than the
trigger value, you will lose a significant portion, and possibly all, of the stated principal amount of the securities. |
| § | You seek an investment that provides for participation in
any upside performance of the underlier above the fixed percentage. |
| § | You are unwilling or unable to accept the risks associated
with an investment linked to the performance of the underlier, as explained in more detail in the “Risk Factors” section of
this document. |
| § | You seek an investment that entitles you to dividends or
distributions on, or voting rights related to, the underlier. |
| § | You seek an investment for which there will be an active
secondary market and/or you are unwilling or unable to hold the securities to maturity. |
| § | You are unwilling or unable to assume our credit risk for
all payments on the securities. |
| § | You are unwilling or unable to consent to the exercise of
any U.K. Bail-in Power by any relevant U.K. resolution authority. |
You must rely on your own evaluation of the merits of an investment
in the securities. You should reach a decision whether to invest in the securities after carefully considering, with your advisors,
the appropriateness of the securities in light of your investment objectives and the specific information set forth in this document,
the prospectus and the prospectus supplement. Neither the issuer nor Barclays Capital Inc. makes any recommendation as to the appropriateness
of the securities for investment.
Trigger Jump Securities Based on the Performance of the Common Stock of Repligen Corporation due May 27, 2026
Principal at Risk Securities
How the Trigger Jump Securities Work
Payoff Diagram
The payoff diagram below illustrates the payment at maturity on the
securities based on the following terms:
| Stated principal amount: |
$1,000 per security |
| Fixed percentage: |
43.20% |
| Trigger value: |
90% of the initial underlier value |
| Minimum payment at maturity: |
None. You could lose your entire initial investment in the securities. |
| Trigger Jump Securities Payoff Diagram |
 |
Scenario Analysis
| § | Upside Scenario. If the final underlier
value is greater than or equal to the initial underlier value, at maturity investors will receive the $1,000 stated principal amount plus
a positive return equal to the fixed percentage of 43.20%. |
| § | For example, if the underlier appreciates by 5%, at maturity
investors would receive a return equal to the fixed percentage of 43.20%, or $1,432.00 per security. |
| § | If the underlier appreciates by 60%, at maturity
investors would receive a return equal to the fixed percentage of 43.20%, or $1,432.00 per security, even
though the underlier has appreciated by more than the fixed percentage. |
| § | Par Scenario. If the final underlier value
is less than the initial underlier value but greater than or equal to the trigger value, at maturity investors will receive the stated
principal amount of $1,000 per security. |
| § | For example, if the underlier depreciates by 5%, at maturity investors would receive the $1,000 stated
principal amount per security. |
Trigger Jump Securities Based on the Performance of the Common Stock of Repligen Corporation due May 27, 2026
Principal at Risk Securities
| § | Downside Scenario. If the final underlier
value is less than the trigger value, at maturity investors will receive an amount that is less than 90% of the $1,000 stated principal
amount and that will reflect a 1% loss of principal for each 1% decline in the underlier. Investors may lose their entire initial investment
in the securities. |
| § | For example, if the underlier depreciates by 50%, investors would lose 50% of their principal and receive
only $500.00 per security at maturity, or 50% of the stated principal amount. |
What Is the Total Return on the Securities at Maturity,
Assuming a Range of Performances for the Underlier?
The following table and examples illustrate
the hypothetical payment at maturity and hypothetical total return at maturity on the securities. The “total return” as used
in this document is the number, expressed as a percentage, that results from comparing the payment at maturity per $1,000 stated principal
amount to $1,000.00. The table and examples set forth below assume a hypothetical initial underlier value of $100.00 and a hypothetical
trigger value of $90.00 (or 90% of the hypothetical initial underlier value) and reflect the fixed percentage of 43.20%. The hypothetical
initial underlier value of $100.00 has been chosen for illustrative purposes only and does not represent the actual initial underlier
value. Please see “Repligen Corporation Overview” below for recent actual values of the underlier. The actual initial underlier
value and trigger value are set forth on the cover page of this document. Each hypothetical payment at maturity or total return set forth
below is for illustrative purposes only and may not be the actual payment at maturity or total return applicable to a purchaser of the
securities. The numbers appearing in the following table and examples have been rounded for ease of analysis. The table and examples below
do not take into account any tax consequences from investing in the securities.
| Final Underlier Value |
Underlier Appreciation / Depreciation |
Underlier Performance Factor |
Payment at Maturity |
Total Return on Securities |
| $170.00 |
70.00% |
N/A |
$1,432.00 |
43.20% |
| $160.00 |
60.00% |
N/A |
$1,432.00 |
43.20% |
| $150.00 |
50.00% |
N/A |
$1,432.00 |
43.20% |
| $143.20 |
43.20% |
N/A |
$1,432.00 |
43.20% |
| $140.00 |
40.00% |
N/A |
$1,432.00 |
43.20% |
| $130.00 |
30.00% |
N/A |
$1,432.00 |
43.20% |
| $120.00 |
20.00% |
N/A |
$1,432.00 |
43.20% |
| $110.00 |
10.00% |
N/A |
$1,432.00 |
43.20% |
| $105.00 |
5.00% |
N/A |
$1,432.00 |
43.20% |
| $100.00 |
0.00% |
N/A |
$1,432.00 |
43.20% |
| $97.50 |
-2.50% |
N/A |
$1,000.00 |
0.00% |
| $95.00 |
-5.00% |
N/A |
$1,000.00 |
0.00% |
| $90.00 |
-10.00% |
N/A |
$1,000.00 |
0.00% |
| $89.99 |
-10.01% |
89.99% |
$899.90 |
-10.01% |
| $80.00 |
-20.00% |
80.00% |
$800.00 |
-20.00% |
| $70.00 |
-30.00% |
70.00% |
$700.00 |
-30.00% |
| $60.00 |
-40.00% |
60.00% |
$600.00 |
-40.00% |
| $50.00 |
-50.00% |
50.00% |
$500.00 |
-50.00% |
| $40.00 |
-60.00% |
40.00% |
$400.00 |
-60.00% |
| $30.00 |
-70.00% |
30.00% |
$300.00 |
-70.00% |
| $20.00 |
-80.00% |
20.00% |
$200.00 |
-80.00% |
| $10.00 |
-90.00% |
10.00% |
$100.00 |
-90.00% |
| $0.00 |
-100.00% |
0.00% |
$0.00 |
-100.00% |
Trigger Jump Securities Based on the Performance of the Common Stock of Repligen Corporation due May 27, 2026
Principal at Risk Securities
Hypothetical Examples of Amount Payable at Maturity
The following examples illustrate how the payment at maturity and total
return in different hypothetical scenarios are calculated.
Example 1: The value of the underlier increases from the initial
underlier value of $100.00 to a final underlier value of $160.00.
Because the final underlier value is greater than or equal to the initial
underlier value, the payment at maturity is calculated as follows:
$1,000 + ($1,000 × fixed percentage)
= $1,000 + ($1,000 × 43.20%)
= $1,432.00
Because the final underlier value is greater than or equal to the initial
underlier value, the payment at maturity is equal to $1,432.00 per security, representing a total return of 43.20% on the securities,
even though the underlier appreciated by 60.00% from its initial underlier value to its final underlier value.
Example 2: The value of the underlier increases from the initial
underlier value of $100.00 to a final underlier value of $110.00.
Because the final underlier value is greater than or equal to the initial
underlier value, the payment at maturity is calculated as follows:
$1,000 + ($1,000 × fixed percentage)
= $1,000 + ($1,000 × 43.20%)
= $1,432.00
Because the final underlier value is greater than or equal to the initial
underlier value, the payment at maturity is equal to $1,432.00 per security, representing a total return of 43.20% on the securities.
Example 3: The value of the underlier decreases from the initial
underlier value of $100.00 to a final underlier value of $95.00.
Because the final underlier value is less than the initial underlier
value but greater than or equal to the trigger value, the payment at maturity is equal to the stated principal amount of $1,000.00 per
security.
The total return on the securities is 0.00%.
Example 4: The value of the underlier decreases from the initial
underlier value of $100.00 to a final underlier value of $50.00.
Because the final underlier value is less than the trigger value and
the underlier performance factor is 50%, the payment at maturity is equal to $500.00 per security, calculated as follows:
$1,000 × underlier performance factor
= $1,000 × (final underlier value / initial
underlier value)
= $1,000 × ($50.00 / $100.00) = $500.00
The total return on the securities is -50.00%.
Trigger Jump Securities Based on the Performance of the Common Stock of Repligen Corporation due May 27, 2026
Principal at Risk Securities
Risk Factors
An investment in the securities involves significant risks. We urge
you to consult your investment, legal, tax, accounting and other advisors before you invest in the securities. Investing in the securities
is not equivalent to investing directly in the underlier. Some of the risks that apply to an investment in the securities are summarized
below, but we urge you to read the more detailed explanation of risks relating to the securities generally in the “Risk Factors”
section of the prospectus supplement. You should not purchase the securities unless you understand and can bear the risks of investing
in the securities.
Risks Relating to the Securities
Generally
| § | The securities do not pay interest or guarantee the return of any principal. The terms of the securities differ from those
of ordinary debt securities in that the securities do not pay interest or guarantee the return of any of the stated principal amount at
maturity. Instead, if the final underlier value is less than the trigger value, which is 90% of the initial underlier value, the payment
at maturity will be an amount in cash that is less than the $1,000 stated principal amount of each security by a percentage equal to the
percentage decrease from the initial underlier value to the final underlier value. There is no minimum payment at maturity on the securities
and, accordingly, you could lose your entire initial investment in the securities. |
| § | The potential return on the securities is limited to the fixed percentage. Any positive
return on your securities will not exceed the fixed percentage, regardless of any appreciation in the value of the underlier, which may
be significant. If the underlier has appreciated since the pricing date by more than the fixed percentage, you will receive a lower return
on the securities than you would have received if you had invested directly in the underlier. |
| § | The fixed percentage provides an enhanced return only for a limited range of positive performance of the underlier. The fixed
percentage enhances returns of the underlier only when the final underlier value is greater than or equal to the initial underlier value
and the underlier has not appreciated by more than the fixed percentage. Accordingly, if the underlier depreciates or if the underlier
appreciates by more than the fixed percentage from the pricing date to the valuation date, the fixed percentage will not enhance the return
on the securities. |
| § | Any payment on the securities will be determined based on the closing prices of the underlier
on the dates specified. Any payment on the securities will be determined based on the closing prices of the underlier on the dates
specified. You will not benefit from any more favorable value of the underlier determined at any other time. |
| § | Investing in the securities is not equivalent to investing in the underlier. Investors
in the securities will not own the underlier or have voting rights or rights to receive dividends or other distributions or any other
rights with respect to the underlier. |
| § | The U.S. federal income tax consequences of an investment in the securities are uncertain. There is no direct legal authority
regarding the proper U.S. federal income tax treatment of the securities, and we do not plan to request a ruling from the Internal Revenue
Service (the “IRS”). Consequently, significant aspects of the tax treatment of the securities are uncertain, and the IRS or
a court might not agree with the treatment of the securities as prepaid forward contracts, as described below under “Additional
provisions—Tax considerations.” If the IRS were successful in asserting an alternative treatment for the securities, the tax
consequences of the ownership and disposition of the securities could be materially and adversely affected. |
In addition, in 2007 the Treasury Department
and the IRS released a notice requesting comments on various issues regarding the U.S. federal income tax treatment of “prepaid
forward contracts” and similar instruments. Any Treasury regulations or other guidance promulgated after consideration of these
issues could materially and adversely affect the tax consequences of an investment in the securities, possibly with retroactive effect.
You should review carefully the sections of the accompanying prospectus supplement entitled “Material U.S. Federal Income Tax Consequences—Tax
Consequences to U.S. Holders—Notes Treated as Prepaid Forward or Derivative Contracts” and, if you are a non-U.S. holder,
“—Tax Consequences to Non-U.S. Holders,” and consult your tax advisor regarding the U.S. federal tax consequences of
an investment in the securities (including possible alternative treatments and the issues presented by the 2007 notice), as well as tax
consequences arising under the laws of any state, local or non-U.S. taxing jurisdiction.
Risks Relating to the Issuer
| § | Credit of issuer. The securities are unsecured and unsubordinated debt obligations of the issuer, Barclays Bank PLC, and are
not, either directly or indirectly, an obligation of any third party. Any payment to be made on the securities, including any repayment
of principal, is subject to the ability of Barclays Bank PLC to satisfy its obligations as they come due and is not guaranteed by any
third party. As a result, the actual and perceived creditworthiness of Barclays Bank PLC may affect the market value of the securities
and, in the event Barclays Bank PLC were to default on its obligations, you might not receive any amount owed to you under the terms of
the securities. |
| § | You may lose some or all of your investment if any U.K. Bail-in Power is exercised by the relevant U.K. resolution authority. Notwithstanding
and to the exclusion of any other term of the securities or any other agreements, arrangements or understandings between Barclays Bank
PLC and any holder or beneficial owner of the securities (or the trustee on behalf of the holders of the securities), by acquiring the
securities, each holder and beneficial owner of the securities acknowledges, accepts, |
Trigger Jump Securities Based on the Performance of the Common Stock of Repligen Corporation due May 27, 2026
Principal at Risk Securities
agrees to be bound by, and consents to
the exercise of, any U.K. Bail-in Power by the relevant U.K. resolution authority as set forth under “Consent to U.K. Bail-in Power”
in this document. Accordingly, any U.K. Bail-in Power may be exercised in such a manner as to result in you and other holders and beneficial
owners of the securities losing all or a part of the value of your investment in the securities or receiving a different security from
the securities, which may be worth significantly less than the securities and which may have significantly fewer protections than those
typically afforded to debt securities. Moreover, the relevant U.K. resolution authority may exercise the U.K. Bail-in Power without providing
any advance notice to, or requiring the consent of, the holders and beneficial owners of the securities. The exercise of any U.K. Bail-in
Power by the relevant U.K. resolution authority with respect to the securities will not be a default or an Event of Default (as each term
is defined in the senior debt securities indenture) and the trustee will not be liable for any action that the trustee takes, or abstains
from taking, in either case, in accordance with the exercise of the U.K. Bail-in Power by the relevant U.K. resolution authority with
respect to the securities. See “Consent to U.K. Bail-in Power” in this document as well as “U.K. Bail-in Power,”
“Risk Factors—Risks Relating to the Securities Generally—Regulatory action in the event a bank or investment firm in
the Group is failing or likely to fail, including the exercise by the relevant U.K resolution authority of a variety of statutory resolution
powers, could materially adversely affect the value of any securities” and “Risk Factors—Risks Relating to the Securities
Generally—Under the terms of the securities, you have agreed to be bound by the exercise of any U.K. Bail-in Power by the relevant
U.K. resolution authority” in the accompanying prospectus supplement.
Risks Relating to the Underlier
| § | No affiliation with the issuer of the underlier. The issuer of the underlier is not an affiliate of ours, is not involved with
this offering in any way, and has no obligation to consider your interests in taking any corporate actions that might affect the value
of the securities. We have not made any due diligence inquiry with respect to the issuer of the underlier in connection with this offering. |
| § | Single equity risk. The price of the underlier can rise or fall sharply due to factors specific to the underlier and its issuer,
such as stock price volatility, earnings, financial conditions, corporate, industry and regulatory developments, management changes and
decisions and other events, as well as general market factors, such as general stock market volatility and levels, interest rates and
economic and political conditions. We urge you to review financial and other information filed periodically with the SEC by the issuer
of the underlier. |
| § | Anti-dilution protection is limited, and the calculation agent has discretion to make anti-dilution adjustments. The calculation
agent may in its sole discretion make adjustments affecting the amounts payable on the securities upon the occurrence of certain corporate
events (such as stock splits or extraordinary or special dividends) that the calculation agent determines have a diluting or concentrative
effect on the theoretical value of the underlier. However, the calculation agent might not make such adjustments in response to all events
that could affect the underlier. The occurrence of any such event and any adjustment made by the calculation agent (or a determination
by the calculation agent not to make any adjustment) may adversely affect the market price of, and any amounts payable on, the securities.
See “Reference Assets—Equity Securities—Share Adjustments Relating to Securities with an Equity Security as a Reference
Asset” in the accompanying prospectus supplement. |
| § | Reorganization or other events could adversely affect the value of the securities or result
in the securities being accelerated. Upon the occurrence of certain reorganization events or a nationalization, expropriation, liquidation,
bankruptcy, insolvency or de-listing of the underlier, the calculation agent will make adjustments to the underlier that may result in
payments on the securities being based on the performance of shares, cash or other assets distributed to holders of the underlier upon
the occurrence of such event or, in some cases, the calculation agent may accelerate the maturity date for a payment determined by the
calculation agent. Any of these actions could adversely affect the value of the underlier and, consequently, the value of the securities.
Any amount payable upon acceleration could be significantly less than the amount(s) that would be due on the securities if they were not
accelerated. However, if we elect not to accelerate the securities, the value of, and any amount payable on, the securities could be adversely
affected, perhaps significantly. See “Reference Assets—Equity Securities—Share Adjustments Relating to Securities with
an Equity Security as a Reference Asset” in the accompanying prospectus supplement. |
| § | Governmental legislative or regulatory actions, such as sanctions, could adversely affect your investment in the securities.
Governmental legislative or regulatory actions, including, without limitation, sanctions-related actions by the U.S. or a foreign government,
could prohibit or otherwise restrict persons from holding the securities or the underlier, or engaging in transactions in them, and any
such action could adversely affect the value of the underlier. These legislative or regulatory actions could result in restrictions on
the securities or the de-listing of the underlier. You may lose a significant portion or all of your initial investment in the securities
if the underlier is de-listed or if you are forced to divest the securities due to government mandates, especially if such de-listing
occurs or such divestment must be made at a time when the value of the securities has declined. See “—Reorganization or other
events could adversely affect the value of the securities or result in the securities being accelerated” above. |
Risks Relating to Conflicts of Interest
| § | We may engage in business with or involving the issuer of the underlier without regard to your interests. We or our affiliates
may presently or from time to time engage in business with the issuer of the underlier without regard to your interests and thus may acquire
non-public information about the issuer of the underlier. Neither we nor any of our affiliates undertakes to |
Trigger Jump Securities Based on the Performance of the Common Stock of Repligen Corporation due May 27, 2026
Principal at Risk Securities
disclose any such information to you. In
addition, we or our affiliates from time to time have published and in the future may publish research reports with respect to the issuer
of the underlier, which may or may not recommend that investors buy or hold the underlier.
| § | Hedging and trading activity by the issuer and its affiliates could potentially adversely affect the value of the securities.
Hedging or trading activities of the issuer’s affiliates and of any other hedging counterparty with respect to the securities could
adversely affect the value of the underlier and, as a result, could decrease the amount an investor may receive on the securities at maturity,
if any. Any of these hedging or trading activities on or prior to the pricing date could have increased the initial underlier value and,
as a result, the trigger value, which is the price at or above which the underlier must close on the valuation date so that the investor
does not suffer a loss on their initial investment in the securities. Additionally, such hedging or trading activities during the term
of the securities, including on the valuation date, could potentially affect the price of the underlier on the valuation date and, accordingly,
the amount of cash an investor will receive at maturity, if any. |
| § | We and our affiliates, and any dealer participating in the distribution of the securities, may engage in various activities or
make determinations that could materially affect your securities in various ways and create conflicts of interest. We and our affiliates
play a variety of roles in connection with the issuance of the securities, as described below. In performing these roles, our and our
affiliates’ economic interests are potentially adverse to your interests as an investor in the securities. |
In connection with our normal business
activities and in connection with hedging our obligations under the securities, we and our affiliates make markets in and trade various
financial instruments or products for our accounts and for the account of our clients and otherwise provide investment banking and other
financial services with respect to these financial instruments and products. These financial instruments and products may include securities,
derivative instruments or assets that may relate to the underlier. In any such market making, trading and hedging activity, investment
banking and other financial services, we or our affiliates may take positions or take actions that are inconsistent with, or adverse to,
the investment objectives of the holders of the securities. We and our affiliates have no obligation to take the needs of any buyer, seller
or holder of the securities into account in conducting these activities. Such market making, trading and hedging activity, investment
banking and other financial services may negatively impact the value of the securities.
In addition, the role played by
Barclays Capital Inc., as the agent for the securities, could present significant conflicts of interest with the role of Barclays Bank
PLC, as issuer of the securities. For example, Barclays Capital Inc. or its representatives may derive compensation or financial benefit
from the distribution of the securities and such compensation or financial benefit may serve as an incentive to sell the securities instead
of other investments. Furthermore, we and our affiliates establish the offering price of the securities for initial sale to the public,
and the offering price is not based upon any independent verification or valuation.
Furthermore, the selected dealer
or its affiliates will have the option to conduct a material portion of the hedging activities for us in connection with the securities.
The selected dealer or its affiliates would expect to realize a projected profit from such hedging activities, and this projected profit
would be in addition to any selling concession that the selected dealer realizes for the sale of the securities to you. This additional
projected profit may create a further incentive for the selected dealer to sell the securities to you.
In addition to the activities described
above, we will also act as the calculation agent for the securities. As calculation agent, we will determine any values of the underlier
and make any other determinations necessary to calculate any payments on the securities. In making these determinations, we may be required
to make discretionary judgments, including determining whether a market disruption event has occurred on any date that the value of the
underlier is to be determined; determining whether to adjust any variable described herein in the case of certain corporate events related
to the underlier that the calculation agent determines have a diluting or concentrative effect on the theoretical value of the shares
of the underlier; and determining whether to accelerate the maturity date upon the occurrence of certain reorganization events and additional
adjustment events. In making these discretionary judgments, our economic interests are potentially adverse to your interests as an investor
in the securities, and any of these determinations may adversely affect any payments on the securities.
Risks Relating to
the Estimated Value of the Securities and the Secondary Market
| § | The securities will not be listed on any securities exchange, and secondary trading may be limited. Barclays Capital Inc. and
other affiliates of Barclays Bank PLC intend to offer to purchase the securities in the secondary market but are not required to do so
and may cease any such market making activities at any time, without notice. Even if a secondary market develops, it may not provide enough
liquidity to allow you to trade or sell the securities easily. Because other dealers are not likely to make a secondary market for the
securities, the price, if any, at which you may be able to trade your securities is likely to depend on the price, if any, at which Barclays
Capital Inc. and other affiliates of Barclays Bank PLC are willing to buy the securities. In addition, Barclays Capital Inc. or one or
more of our other affiliates may at any time hold an unsold portion of the securities (as described on the cover page of this document),
which may inhibit the development of a secondary market for the securities. The securities are not designed to be short-term trading instruments.
Accordingly, you should be willing and able to hold your securities to maturity. |
| § | The market price of the securities will be influenced by many unpredictable factors. Several factors will influence the value
of the securities in the secondary market and the price at which Barclays Capital Inc. and other affiliates of Barclays Bank PLC may be
willing to purchase or sell the securities in the secondary market. Although we expect that generally the value of the underlier on |
Trigger Jump Securities Based on the Performance of the Common Stock of Repligen Corporation due May 27, 2026
Principal at Risk Securities
any day will affect the value of the securities
more than any other single factor, other factors that may influence the value of the securities include:
| o | the volatility (frequency and magnitude of changes in value) of the underlier; |
| o | dividend rates on the underlier; |
| o | interest and yield rates in the market; |
| o | time remaining until the securities mature; |
| o | supply and demand for the securities; |
| o | geopolitical conditions and economic, financial, political, regulatory and judicial events that affect the underlier and that may
affect the final underlier value; and |
| o | any actual or anticipated changes in our credit ratings or credit spreads. |
The value of the underlier may be,
and has recently been, volatile, and we can give you no assurance that the volatility will lessen. See “Repligen Corporation Overview”
below. You may receive less, and possibly significantly less, than the stated principal amount if you try to sell your securities prior
to maturity.
| § | The estimated value of your securities is lower than the initial issue price of your securities. The estimated value of your
securities on the pricing date is lower than the initial issue price of your securities. The difference between the initial issue price
of your securities and the estimated value of the securities is a result of certain factors, such as any sales commissions to be paid
to Barclays Capital Inc. or another affiliate of ours, any selling concessions, discounts, commissions or fees to be allowed or paid to
non-affiliated intermediaries, the estimated profit that we or any of our affiliates expect to earn in connection with structuring the
securities, the estimated cost that we may incur in hedging our obligations under the securities, and estimated development and other
costs that we may incur in connection with the securities. These other costs will include a fee paid to LFT Securities, LLC, an entity
in which an affiliate of Morgan Stanley Wealth Management has an ownership interest, for providing certain electronic platform services
with respect to this offering. |
| § | The estimated value of your securities might be lower if such estimated value were based on the levels at which our debt securities
trade in the secondary market. The estimated value of your securities on the pricing date is based on a number of variables, including
our internal funding rates. Our internal funding rates may vary from the levels at which our benchmark debt securities trade in the secondary
market. As a result of this difference, the estimated value referenced above might be lower if such estimated value were based on the
levels at which our benchmark debt securities trade in the secondary market. |
| § | The estimated value of the securities is based on our internal pricing models, which may prove to be inaccurate and may be different
from the pricing models of other financial institutions. The estimated value of your securities on the pricing date is based on our
internal pricing models, which take into account a number of variables and are based on a number of subjective assumptions, which may
or may not materialize. These variables and assumptions are not evaluated or verified on an independent basis. Further, our pricing models
may be different from other financial institutions’ pricing models and the methodologies used by us to estimate the value of the
securities may not be consistent with those of other financial institutions that may be purchasers or sellers of securities in the secondary
market. As a result, the secondary market price of your securities may be materially different from the estimated value of the securities
determined by reference to our internal pricing models. |
| § | The estimated value of your securities is not a prediction of the prices at which you may sell your securities in the secondary
market, if any, and such secondary market prices, if any, will likely be lower than the initial issue price of your securities and may
be lower than the estimated value of your securities. The estimated value of the securities will not be a prediction of the prices
at which Barclays Capital Inc., other affiliates of ours or third parties may be willing to purchase the securities from you in secondary
market transactions (if they are willing to purchase, which they are not obligated to do). The price at which you may be able to sell
your securities in the secondary market at any time will be influenced by many factors that cannot be predicted, such as market conditions,
and any bid and ask spread for similar sized trades, and may be substantially less than our estimated value of the securities. Further,
as secondary market prices of your securities take into account the levels at which our debt securities trade in the secondary market,
and do not take into account our various costs related to the securities such as fees, commissions, discounts, and the costs of hedging
our obligations under the securities, secondary market prices of your securities will likely be lower than the initial issue price of
your securities. As a result, the price at which Barclays Capital Inc., other affiliates of ours or third parties may be willing to purchase
the securities from you in secondary market transactions, if any, will likely be lower than the price you paid for your securities, and
any sale prior to the maturity date could result in a substantial loss to you. |
| § | The temporary price at which we may initially buy the securities in the secondary market and the value we may initially use for
customer account statements, if we provide any customer account statements at all, may not be indicative of future prices of your securities.
Assuming that all relevant factors remain constant after the pricing date, the price at which Barclays Capital Inc. may initially buy
or sell the securities in the secondary market (if Barclays Capital Inc. makes a market in the securities, which it is not obligated to
do) and the value that we may initially use for customer account statements, if we provide any customer account statements at all, may
exceed our estimated value of the securities on the pricing date, as well as the secondary |
Trigger Jump Securities Based on the Performance of the Common Stock of Repligen Corporation due May 27, 2026
Principal at Risk Securities
market value of the securities, for a temporary
period after the initial issue date of the securities. The price at which Barclays Capital Inc. may initially buy or sell the securities
in the secondary market and the value that we may initially use for customer account statements may not be indicative of future prices
of your securities.
Trigger Jump Securities Based on the Performance of the Common Stock of Repligen Corporation due May 27, 2026
Principal at Risk Securities
Repligen Corporation Overview
According to publicly available information, Repligen Corporation (the
“Company”) is a life sciences company that develops and commercializes bioprocessing technologies and systems that increase
efficiencies and flexibility in manufacturing biological drugs.
Information filed by the Company with the SEC under the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), can be located by reference to its SEC file number: 000-14656. The Company’s
common stock is listed on The Nasdaq Stock Market under the ticker symbol “RGEN.”
We urge you to read the following section in the accompanying prospectus
supplement: “Reference Assets—Equity Securities—Reference Asset Issuer and Reference Asset Information.” Companies
with securities registered under the Exchange Act are required to file financial and other information specified by the SEC periodically.
Information provided to or filed with the SEC by the Company can be located on a website maintained by the SEC at http://www.sec.gov by
reference to the Company’s SEC file number provided above.
The summary information above regarding the Company comes from the Company’s
SEC filings. You are urged to refer to the SEC filings made by the Company and to other publicly available information (such as the Company’s
annual report) to obtain an understanding of the Company’s business and financial prospects. The summary information contained above
is not designed to be, and should not be interpreted as, an effort to present information regarding the financial prospects of any issuer
or any trends, events or other factors that may have a positive or negative influence on those prospects or as an endorsement of any particular
issuer.
Information from outside sources is not incorporated by reference
in, and should not be considered part of, this document or the accompanying prospectus or prospectus supplement. We have not independently
verified the accuracy or completeness of the information contained in outside sources.
Information about the underlier as of market close on November 21, 2024:
| Bloomberg Ticker Symbol: |
RGEN UW |
52 Week High: |
$208.42 |
| Current Closing Price: |
$141.76 |
52 Week Low: |
$119.79 |
| 52 Weeks Ago (11/22/2023): |
$160.21 |
|
|
The following table sets forth the published high, low and period-end
closing prices of the underlier for each quarter for the period of January 2, 2019 through November 21, 2024. The associated graph shows
the closing prices of the underlier for each day in the same period. The closing price of the underlier on November 21, 2024 was $141.76.
We obtained the closing prices of the underlier from Bloomberg Professional® service, without independent verification.
Historical performance of the underlier should not be taken as an indication of future performance. Future performance of the underlier
may differ significantly from historical performance, and no assurance can be given as to the closing price of the underlier during the
term of the securities, including on the valuation date. We cannot give you assurance that the performance of the underlier will not result
in a loss on your initial investment. The closing prices below may have been adjusted to reflect certain corporate actions, such as
stock splits, public offerings, mergers and acquisitions, spin-offs, extraordinary dividends, delistings and bankruptcy.
| Common Stock of Repligen Corporation |
High |
Low |
Period End |
| 2019 |
|
|
|
| First Quarter |
$62.80 |
$49.45 |
$59.08 |
| Second Quarter |
$85.95 |
$54.20 |
$85.95 |
| Third Quarter |
$95.51 |
$76.65 |
$76.69 |
| Fourth Quarter |
$93.08 |
$73.84 |
$92.50 |
| 2020 |
|
|
|
| First Quarter |
$109.14 |
$84.96 |
$96.54 |
| Second Quarter |
$140.48 |
$94.33 |
$123.61 |
| Third Quarter |
$158.27 |
$122.51 |
$147.54 |
| Fourth Quarter |
$206.57 |
$148.08 |
$191.63 |
| 2021 |
|
|
|
| First Quarter |
$226.26 |
$180.37 |
$194.41 |
| Second Quarter |
$220.95 |
$165.87 |
$199.62 |
| Third Quarter |
$324.21 |
$194.77 |
$288.99 |
| Fourth Quarter |
$304.47 |
$247.59 |
$264.84 |
Trigger Jump Securities Based on the Performance of the Common Stock of Repligen Corporation due May 27, 2026
Principal at Risk Securities
| Common Stock of Repligen Corporation |
High |
Low |
Period End |
| 2022 |
|
|
|
| First Quarter |
$257.96 |
$161.19 |
$188.09 |
| Second Quarter |
$188.02 |
$140.68 |
$162.40 |
| Third Quarter |
$256.21 |
$160.42 |
$187.11 |
| Fourth Quarter |
$220.56 |
$162.42 |
$169.31 |
| 2023 |
|
|
|
| First Quarter |
$198.10 |
$154.26 |
$168.36 |
| Second Quarter |
$180.31 |
$138.42 |
$141.46 |
| Third Quarter |
$176.51 |
$138.78 |
$159.01 |
| Fourth Quarter |
$185.35 |
$114.17 |
$179.80 |
| 2024 |
|
|
|
| First Quarter |
$208.42 |
$170.78 |
$183.92 |
| Second Quarter |
$182.95 |
$120.00 |
$126.06 |
| Third Quarter |
$167.35 |
$119.79 |
$148.82 |
| Fourth Quarter (through November 21, 2024) |
$150.47 |
$123.41 |
$141.76 |
|
|
|
|
Underlier Historical Performance*—
January 2, 2019 to November 21, 2024 |
 |
| * The dotted line indicates the trigger value of 90% of the initial underlier value. |
PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE
RESULTS.
Trigger Jump Securities Based on the Performance of the Common Stock of Repligen Corporation due May 27, 2026
Principal at Risk Securities
Additional Information about the Securities
Please read this information in conjunction with the terms on the cover
page of this document.
| Additional provisions: |
|
| Minimum ticketing size: |
$1,000 / 1 security |
| Tax considerations: |
You should review carefully the sections in the accompanying prospectus
supplement entitled “Material U.S. Federal Income Tax Consequences—Tax Consequences to U.S. Holders—Notes Treated as
Prepaid Forward or Derivative Contracts” and, if you are a non-U.S. holder, “—Tax Consequences to Non-U.S. Holders.”
The following discussion, when read in combination with those sections, constitutes the full opinion of our special tax counsel, Davis
Polk & Wardwell LLP, regarding the material U.S. federal income tax consequences of owning and disposing of the securities. The following
discussion supersedes the discussion in the accompanying prospectus supplement to the extent it is inconsistent therewith.
Based on current market conditions, in the opinion of our special tax
counsel, the securities should be treated for U.S. federal income tax purposes as prepaid forward contracts with respect to the underlier.
Assuming this treatment is respected, upon a sale or exchange of the securities (including redemption at maturity), you should recognize
capital gain or loss equal to the difference between the amount realized on the sale or exchange and your tax basis in the securities,
which should equal the amount you paid to acquire the securities. This gain or loss on your securities should be treated as long-term
capital gain or loss if you hold your securities for more than a year, whether or not you are an initial purchaser of securities at the
original issue price.
However, the IRS or a court may not respect this treatment, in which
case the timing and character of any income or loss on the securities could be materially and adversely affected. In addition, in 2007
the U.S. Treasury Department and the IRS released a notice requesting comments on the U.S. federal income tax treatment of “prepaid
forward contracts” and similar instruments. The notice focuses in particular on whether to require investors in these instruments
to accrue income over the term of their investment. It also asks for comments on a number of related topics, including the character of
income or loss with respect to these instruments; the relevance of factors such as the nature of the underlying property to which the
instruments are linked; the degree, if any, to which income (including any mandated accruals) realized by non-U.S. investors should be
subject to withholding tax; and whether these instruments are or should be subject to the “constructive ownership” regime,
which very generally can operate to recharacterize certain long-term capital gain as ordinary income and impose a notional interest charge.
While the notice requests comments on appropriate transition rules and effective dates, any Treasury regulations or other guidance promulgated
after consideration of these issues could materially and adversely affect the tax consequences of an investment in the securities, possibly
with retroactive effect. You should consult your tax advisor regarding the U.S. federal income tax consequences of an investment in the
securities, including possible alternative treatments and the issues presented by this notice.
Treasury regulations under Section 871(m) generally impose a withholding
tax on certain “dividend equivalents” under certain “equity linked instruments.” A recent IRS notice excludes
from the scope of Section 871(m) instruments issued prior to January 1, 2027 that do not have a “delta of one” with respect
to underlying securities that could pay U.S.-source dividends for U.S. federal income tax purposes (each an “Underlying Security”).
Based on our determination that the securities do not have a “delta of one” within the meaning of the regulations, our special
tax counsel is of the opinion that these regulations should not apply to the securities with regard to non-U.S. holders. Our determination
is not binding on the IRS, and the IRS may disagree with this determination. Section 871(m) is complex and its application may depend
on your particular circumstances, including whether you enter into other transactions with respect to an Underlying Security. You should
consult your tax advisor regarding the potential application of Section 871(m) to the securities.
|
| Trustee: |
The Bank of New York Mellon |
| Use of proceeds and hedging: |
The net proceeds we receive from the sale of the
securities will be used for various corporate purposes as set forth in the prospectus and prospectus supplement and, in part, in
connection with hedging our obligations under the securities through one or more of our subsidiaries.
We, through our subsidiaries or others, hedge our
anticipated exposure in connection with the securities by taking positions in futures and options contracts on the underlier and
any other securities or instruments we may wish to use in connection with such hedging. Trading and other transactions by us or our
affiliates could affect the value of the underlier, the market value of the securities or any amounts payable on the securities. For
further information on our use of proceeds and hedging, see
|
Trigger Jump Securities Based on the Performance of the Common Stock of Repligen Corporation due May 27, 2026
Principal at Risk Securities
| |
“Use of Proceeds and Hedging” in the prospectus supplement. |
| ERISA: |
See “Benefit Plan Investor Considerations” in the accompanying prospectus supplement. |
| Validity of the securities: |
In the opinion of Davis Polk & Wardwell LLP, as special United States products counsel to Barclays Bank PLC, when the securities offered by this pricing supplement have been executed and issued by Barclays Bank PLC and authenticated by the trustee pursuant to the indenture, and delivered against payment as contemplated herein, such securities will be valid and binding obligations of Barclays Bank PLC, enforceable in accordance with their terms, subject to applicable bankruptcy, insolvency and similar laws affecting creditors’ rights generally, concepts of reasonableness and equitable principles of general applicability (including, without limitation, concepts of good faith, fair dealing and the lack of bad faith) and possible judicial or regulatory actions or application giving effect to governmental actions or foreign laws affecting creditors’ rights, provided that such counsel expresses no opinion as to the effect of fraudulent conveyance, fraudulent transfer or similar provision of applicable law on the conclusions expressed above. This opinion is given as of the date hereof and is limited to the laws of the State of New York. Insofar as this opinion involves matters governed by English law, Davis Polk & Wardwell LLP has relied, with Barclays Bank PLC’s permission, on the opinion of Davis Polk & Wardwell London LLP, dated as of July 12, 2024, filed as an exhibit to a report on Form 6-K by Barclays Bank PLC on July 12, 2024, and this opinion is subject to the same assumptions, qualifications and limitations as set forth in such opinion of Davis Polk & Wardwell London LLP. In addition, this opinion is subject to customary assumptions about the trustee’s authorization, execution and delivery of the indenture and its authentication of the securities and the validity, binding nature and enforceability of the indenture with respect to the trustee, all as stated in the opinion of Davis Polk & Wardwell LLP, dated July 12, 2024, which has been filed as an exhibit to the report on Form 6-K referred to above. |
This document represents a summary of the terms and conditions of
the securities. We encourage you to read the accompanying prospectus and prospectus supplement for this offering, which can be accessed
via the hyperlinks on the cover page of this document.
Supplemental Plan of Distribution
Morgan Stanley Smith Barney LLC (“Morgan Stanley Wealth Management”)
and its financial advisors will collectively receive from the agent, Barclays Capital Inc., a fixed sales commission for each security
they sell, and Morgan Stanley Wealth Management will receive a structuring fee for each security, in each case as specified on the cover
page of this document.
We expect that delivery of the securities will be made against payment
for the securities on the original issue date, which is more than one business day following the pricing date. Notwithstanding anything
to the contrary in the accompanying prospectus supplement, under Rule 15c6-1 of the Securities Exchange Act of 1934, as amended, effective
May 28, 2024, trades in the secondary market generally are required to settle in one business day, unless the parties to any such trade
expressly agree otherwise. Accordingly, purchasers who wish to trade the securities on any date prior to one business day before delivery
will be required to specify alternative settlement arrangements to prevent a failed settlement and should consult their own advisor.
Exhibit
107.1
Calculation
of Filing Fee Table
F-3
(Form Type)
Barclays
Bank PLC
(Exact Name of Registrant as Specified in its Charter)
Table
1—Newly Registered Securities
| |
Security
Type |
Security
Class Title |
Fee
Calculation or Carry Forward Rule |
Amount
Registered |
Proposed
Maximum Offering Price Per Unit |
Maximum
Aggregate Offering Price |
Fee
Rate |
Amount
of Registration Fee |
| Fees
to be Paid |
Debt |
Global
Medium-Term Notes, Series A |
457(r) |
10,000 |
$1,000 |
$10,000,000 |
0.0001531 |
$1,531.00 |
The
pricing supplement to which this Exhibit is attached is a final prospectus for the related offering.
iPath Bloomberg Platinum... (PK) (USOTC:PGMFF)
Historical Stock Chart
From Oct 2024 to Nov 2024
iPath Bloomberg Platinum... (PK) (USOTC:PGMFF)
Historical Stock Chart
From Nov 2023 to Nov 2024
